Introduction
============

Thrombosis is a common pathology underlying venous thromboembolism (VTE), as well as ischemic heart disease and ischemic stroke, and is a leading cause of morbidity and mortality worldwide.^[@b1-1051677]^ Thrombus formation involves platelet activation and aggregation as well as local, vascular tissue factor (TF) expression and activation, which may result in occlusion of blood vessels and ischemic events.^[@b2-1051677]--[@b6-1051677]^ The expression of TF, a transmembrane protein, is highly induced in both vascular smooth muscle cells (SMC) and endothelial cells (EC) in response to vascular injury.^[@b7-1051677]--[@b10-1051677]^ Upon injury to the vessel wall, TF is exposed to blood coagulation factors. The TF-factor VIIa complex catalyzes the proteolytic activation of coagulation factor X, leading to generation of the multi-purpose enzyme thrombin, which converts fibrinogen into fibrin, activates platelets, induces thrombus formation, and initiates protease-activated receptor (PAR) signaling.^[@b11-1051677],[@b12-1051677]^ It has been demonstrated that TF expression is induced on vascular cells such as EC and SMC as well as on immune cells such as monocytes and may play a pivotal role in a variety of pathological conditions, including acute coronary syndromes, thrombosis, sickle cell disease, diabetes, anti-phospholipid antibody syndrome, septic shock, and cancer.^[@b2-1051677],[@b4-1051677],[@b13-1051677]--[@b20-1051677]^ Furthermore, TF is detectable in macrophages, pericytes and adventitial fibroblasts of normal arteries.^[@b21-1051677]^

Inflammatory mediators such as tumor necrosis factor-α (TNF- α) and pro-thrombotic factors promoting thrombus formation (for example thrombin) have been shown to increase TF expression in vascular cells including EC and SMC.^[@b22-1051677]--[@b24-1051677]^ The regulation of TF transcription in EC and SMC, and circulating cells has been described extensively and involves numerous transcription factors such as activating protein-1 (AP-1) and nuclear factor-κB (NFκB).^[@b25-1051677],[@b26-1051677]^ In order to identify individuals at risk of thrombosis and to design innovative therapeutic strategies inhibiting thrombus formation in the above-mentioned pathological conditions, it is crucial to identify key factors regulating TF expression and activity in EC and SMC.

LIM-only protein FHL2 is a member of the four and a half LIM (FHL) protein family and is composed of an N-terminal half LIM domain followed by four complete LIM domains.^[@b27-1051677]--[@b31-1051677]^ LIM domains contain double zinc finger structures that mediate protein-protein interactions and, unlike other zinc finger structures, show no affinity for DNA. Rather, FHL2 has been shown to interact with a plethora of proteins including nuclear receptors such as Nur77, liver X receptors, androgen receptor, estrogen receptor, and other transcription factors such as AP-1 and NFκB.^[@b27-1051677]--[@b31-1051677]^ FHL2 is a multifunctional protein and acts as a transcriptional coactivator or corepressor in a cell- and context-dependent manner. Cumulative evidence shows that FHL2 is implicated in a range of physiological and pathological processes, such as cell proliferation, differentiation, migration, and apoptosis, bone formation, wound healing and inflammation.^[@b27-1051677]--[@b31-1051677]^ FHL2 is highly expressed in vascular cells including EC and SMC,^[@b28-1051677]--[@b31-1051677]^ which is relevant for the current study.

In this study, we investigated the impact of FHL2 on venous thrombosis using ferric chloride (FeCl~3~)-induced vascular injury of murine mesenteric vessels. We also demonstrated that FHL2 inhibits TF expression and activity in EC and SMC. Insight into the molecular mechanisms governing this regulation involves evidence that FHL2 regulates *TF* gene expression in an AP-1- and NFκB-dependent manner. Furthermore, we found that FHL2 physically interacts with TF, together modulating local thrombus formation in mice in response to vascular injury. Finally, we identified that the single nucleotide polymorphism (SNP) rs4851770 in the *FHL2* gene is associated with venous thrombosis in humans.

Methods
=======

The methods are described in detail in the *Online Supplement*.

*In vivo* thrombosis in mesenteric veins
----------------------------------------

Five-week old male *FHL2*-knockout (KO) mice and respective wildtype (WT) littermate mice (C57BL/6; n=8 per group) were anesthetized by isoflurane (2% for induction, 1.6-1.8% to maintain anesthesia during imaging) and thrombus formation in the mesenteric veins was provoked as described previously.^[@b32-1051677]^ Animals were handled in accordance with national and European animal experimental protocols.

Cell culture and transfection
-----------------------------

HEK293T, human umbilical vein endothelial cells (HUVEC), murine and human SMC, and murine macrophages were cultured as described previously.^[@b28-1051677]--[@b30-1051677],[@b33-1051677],[@b34-1051677]^ Human microvascular endothelial cells (HMEC-1) were cultured in MCDB131 medium (Gibco, Blijswijk, the Netherlands) supplemented with 10% fetal calf serum, epidermal growth factor, penicillin/streptomycin, and L-glutamine. The human endothelial cell line ECRF was cultured in EGM2 medium (Lonza, Basel, Switzerland).

Real-time polymerase chain reaction, western blot, protein stability and co-immunoprecipitation assays
------------------------------------------------------------------------------------------------------

Real-time polymerase chain reaction analysis, western blot, protein stability and co-immunoprecipitation assays were performed as described previously.^[@b28-1051677],[@b29-1051677]^

*FHL2* knockdown
----------------

Recombinant lentiviral particles encoding *FHL2* and short hairpin RNA (shRNA) targeting *FHL2* were produced, concentrated, and titrated as described previously.^[@b24-1051677]^

Tissue factor activity and luciferase assays
--------------------------------------------

TF activity in HUVEC and SMC was assayed as previously described.^[@b35-1051677]^

Luciferase assays were performed as described previously using TF-promoter luciferase reporter plasmids and full-length FHL2 or FHL2 variants.^[@b28-1051677],[@b29-1051677],[@b36-1051677]^

Single nucleotide polymorphism association in patients with venous thromboembolism
----------------------------------------------------------------------------------

To study the association between *FHL2* and VTE, a two-step validation study was designed, consisting of discovery and replication phases. For the discovery phase, 18 *FHL2* SNP (listed in [Table 1](#t1-1051677){ref-type="table"}) were tested. In collaboration with the International Network against VENous Thrombosis (INVENT) consortium, the association between these candidate SNP and venous thrombosis was assessed. Details about the design of the INVENT genome-wide association study have been previously published.^[@b37-1051677]^ To obtain replication evidence, SNP rs4851770 (*P*\<0.000201) was selected for genotyping in The Thrombophilia, Hypercoagulability and Environmental Risks in Venous Thromboembolism (THE-VTE) case-control study including 676 patients with a first objectively diagnosed episode of deep venous thrombosis aged 18-70 years and 368 control subjects. This two-center, case--control study has been previously described.^[@b38-1051677]^ Human studies were performed with patients' consent and approval from the institutional review boards of participating research centers and hospitals.

###### 

*FHL2* single nucleotide polymorphism analyses in the INVENT cohort.

![](1051677.tab1)

Statistical analysis
--------------------

All statistical analyses were carried out with GraphPad Prism software (GraphPad Software, San Diego, CA, USA). Comparisons between two groups were done with the Student *t* test for unpaired variables. Comparisons between more than two groups were testesd by analysis of variance (ANOVA). Data are reported as mean ± standard deviation. *P* values \<0.05 were considered statistically significant.

The *P* values obtained from the INVENT genome-wide association study were corrected using the Bonferroni adjustment. In the THE-VTE study, the association of the genotyped SNP with the risk of a first venous thrombosis was assessed by calculating odds ratios (OR) with corresponding 95% confidence intervals (95% CI) adjusted for age and sex, using SPSS (SPSS Inc, Chicago, IL, USA). Analyses were performed in the overall group of patients and after stratification into groups with provoked or unprovoked first venous thrombosis. An unprovoked venous thrombosis was defined as an event in the absence of surgery, plaster cast, injury, immobilization for more than four consecutive days, hospitalization, pregnancy or postpartum status, or hormone use in the 3 months prior to the event.^[@b37-1051677]^

Results
=======

FHL2-deficient mice show enhanced thrombus formation upon vascular injury
-------------------------------------------------------------------------

We previously reported that FHL2 deficiency causes enhanced arterial lesion formation in the murine model of carotid artery ligation.^[@b30-1051677]^ Interestingly, even 4 weeks after ligation, thrombus formation was observed in sections of the ligated arteries in five of 14 *FHL2*-KO mice, whereas such structures were absent in the vascular lesions of WT mice (*data not shown*). We therefore hypothesized that FHL2 may be involved in thrombus formation. To substantiate this hypothesis, we performed FeCl~3~-induced thrombosis experiments in WT and *FHL2*-KO mice. Upon FeCl~3~-induced vascular injury, the blood flow in mesenteric veins was imaged by intravital microscopy to assess thrombus formation. Platelets were visualized with an anti-GPIbβ antibody and fluorescent fibrinogen was injected to monitor fibrin accumulation ([Figure 1A](#f1-1051677){ref-type="fig"}). The time from vessel injury to formation of a stable occlusive thrombus (time to occlusion) was 2.3-fold shorter in *FHL2*-KO mice, suggesting that FHL2 has an inhibitory function in thrombus formation following vascular injury ([Figure 1B](#f1-1051677){ref-type="fig"}). Enhanced fibrin formation was observed in vessels of *FHL2*-KO animals and was visible as intense red fluorescence (*Online Supplementary Figure S1*). Since FeCl~3~-induced thrombus formation involves TF expression and activity in the vessel wall,^[@b39-1051677]^ we next studied the impact of FHL2 on this aspect in EC and SMC.

![FHL2-deficient mice show enhanced thrombus formation upon vascular injury. Ferric chloride (FeCl~3~)-induced thrombus formation in wildtype (WT) and FHL2-deficient (*FHL2*-KO) mice. (A) Representative photomicrographs are shown at different time points after injury in mesenteric vessels of WT and *FHL2*-KO mice. Platelets were visualized with a fluorescently labeled antibody (green) and labeled fibrinogen was injected to visualize fibrin formation in the thrombus (red). (B) The time to occlusion was assessed, revealing a 2.3-fold faster occlusion in *FHL2*-KO mice compared to WT animals. Data represent means ± standard deviation. \**P*\<0.05; n=8.](1051677.fig1){#f1-1051677}

FHL2 deficiency enhances tissue factor expression
-------------------------------------------------

Given that TF expression in SMC is required for FeCl~3~-induced vascular injury, we hypothesized that FHL2 may have a function in modulating TF expression in EC and SMC.^[@b40-1051677]^ We therefore determined TF expression in the endothelial cell line ECRF and in HUVEC following overexpression of FHL2. Ectopic expression of FHL2 reduced TNFα-induced TF mRNA and protein expression in ECRF cells and HUVEC ([Figure 2A--C](#f2-1051677){ref-type="fig"}; *Online Supplementary Figure S2A*). Similar results were observed in human microvascular endothelial cells (*data not shown*).

![FHL2 modulates tissue factor expression in endothelial cells and smooth muscle cells. (A) Tissue factor (TF) mRNA levels were determined by real-time quantitative polymerase chain reaction (qRT-PCR) in ECRF cells (A) and in human umbilical vein endothelial cells (HUVEC) (B) transduced with control lentivirus (Mock) or *FHL2*-encoding virus after treatment with tumor necrosis factor-α (TNFα) (C) Western blot analysis of TF protein expression in HUVEC following ectopic expression of FHL2 and stimulation with TNFα. (D) Western blot analysis of TF in aortic smooth muscle cells (SMC) derived from wildtype (WT) and *FHL2*-knockout (KO) mice. Tubulin was used as a loading control. (E) To assess mRNA expression of TF in the aortic SMC isolated from WT and *FHL2*-KO mice, qRT-PCR was performed. (F) *TF* mRNA levels were determined by qRT-PCR in WT and *FHL2*-KO SMC stimulated with macrophage-conditioned medium (an atherogenic stimulus, see Methods) for the indicated time periods. (G) WT and *FHL2*-KO SMC were transduced with lentiviral particles encoding control (Mock) or *FHL2* and assayed for *TF* mRNA expression by qRT-PCR. (H) Gain-of-function and (I) knockdown of *FHL2* in human SMC, after which mRNA expression of *TF* was determined. Data represent means ± standard deviation (SD). \**P*\<0.05. shCtrl, short-hairpin control. a.u, arbitrary units. (J) Human SMC were transduced with lentiviral particles encoding control (Mock) or *FHL2* and western blot analysis was performed to assess TF protein levels. In all qRT-PCR experiments acidic ribosomal phosphoprotein P0 was determined as an internal control for cDNA content of the samples and data are represented as means ± SD. \**P*\<0.05. Western blot analyses were performed to assess TF protein levels and β-actin was used as a loading control. n=3](1051677.fig2){#f2-1051677}

Next, we cultured SMC of WT and *FHL2*-KO mice and assessed the expression of TF. *TF* mRNA expression was significantly higher in SMC cultured from *FHL2*-KO than in those from WT mice ([Figure 2D--E](#f2-1051677){ref-type="fig"}; *Online Supplementary Figure S2C*). The expression of TF in SMC was increased in response to a conditioned medium of macrophages stimulated with oxidized low density lipoproteins, which may be considered as an atherogenic stimulus.^[@b33-1051677]^ Also under these conditions TF expression was higher in *FHL2*- KO SMC than in WT cells ([Figure 2F](#f2-1051677){ref-type="fig"}). Subsequently, gain-of-function experiments were performed in both WT and *FHL2*-KO SMC (FHL2 expression is shown in *Online Supplementary Figure S2D*). FHL2 downregulated TF expression in both WT and *FHL2*-KO SMC ([Figure 2G](#f2-1051677){ref-type="fig"}). Similarly, in human SMC the expression of TF mRNA and protein decreased following ectopic FHL2 expression ([Figure 2H, J](#f2-1051677){ref-type="fig"}; *Online Supplementary Figure S2B*), whereas knockdown of FHL2 in human SMC resulted in enhanced expression of *TF* mRNA ([Figure 2I](#f2-1051677){ref-type="fig"}; FHL2 expression is shown in *Online Supplementary Figure S2E*). Furthermore, we confirmed increased *TF* expression in *FHL2*-KO mice in RNA samples from isolated carotid arteries after carotid artery ligation for 1, 2 and 4 weeks and in intact, isolated mouse aorta to rule out confounding tissue culture-related effects (*Online Supplementary Figure S3A, B*). We also demonstrated that bone-marrow derived macrophages from *FHL2*-KO mice showed increased mRNA levels of TF under basal, lipopolysaccharide-, and interleukin-4-stimulated conditions compared to macrophages derived from WT mice (*Online Supplementary Figure S3C*). Together, these data indicate that FHL2 inhibits TF expression in EC, SMC and macrophages.

FHL2 regulates tissue factor expression through inhibition of nuclear factor κB and activating protein-1
--------------------------------------------------------------------------------------------------------

FHL2 does not bind DNA directly but is known to affect the activity of genuine transcription factors such as NFκB and AP-1. The TF promoter contains functional binding motifs for NFκB and AP-1.^[@b25-1051677],[@b26-1051677]^ To elucidate the mechanism by which FHL2 suppresses transcription of the *TF* gene, we performed transient transfections with WT and mutant TF promoter-reporter constructs in HEK293T cells ([Figure 3A](#f3-1051677){ref-type="fig"}). FHL2 expression decreased the luciferase activity of the WT TF-promoter reporter ([Figure 3B](#f3-1051677){ref-type="fig"}). TF promoter constructs with either a disrupted NFκB response element or a mutated AP-1 element exhibited lower basal luciferase activity ([Figure 3B](#f3-1051677){ref-type="fig"}) and FHL2-mediated inhibition of luciferase activity of the WT-promoter (61%) was stronger than that of the NFκB- or AP-1-mutated promoter (52% and 43%, respectively) ([Figure 3B](#f3-1051677){ref-type="fig"}). These data suggest that FHL2 affects the transcriptional activity of both NFκB and AP-1 to downregulate TF-promoter activity in these cells. To assess whether activation of EC affects cellular localization of FHL2, we stimulated EC with TNF-α (50 ng/mL) and observed enhanced nuclear localization, which may contribute to the changed modulation of transcription factor activity by FHL2 (*Online Supplementary Figure S4*). To determine which domain of FHL2 is essential to inhibit TF-promoter activity, deletion mutants of FHL2^[@b28-1051677]^ ([Figure 3C](#f3-1051677){ref-type="fig"}) were tested in TF-promoter luciferase assays. The first one and a half LIM-domain (LIM0-1) already exhibited partial inhibition (41%) with the LIM0-2 variant having similar effects, while LIM0-3 (55% inhibition) and FHL2 were more potent inhibitors of TF-promoter activity ([Figure 3D](#f3-1051677){ref-type="fig"}). Of note, overexpression of individual LIM domains of FHL2 had no effect on TF promoter activity (*data not shown*) indicating that at least one and a half LIM domains of FHL2 are required to elicit decreased TF-promoter activity.

![FHL2-mediated regulation of tissue factor promoter luciferase reporter. (A) Schematic representation of the normal (WT) and mutant human tissue factor (TF) promoter-reporter constructs that were used. (B) Transient co-transfection of 293T cells was performed with either TF-Luc (WT), NFκB mut-Luc and AP-1 mut-Luc in combination with either a control plasmid (Mock) or a plasmid encoding *FHL2* and luciferase activity was measured after stimulating the cells with phorbol myristate acetate (PMA). (C) Schematic representation of the *FHL2* variants that were tested. (D) The effect of *FHL2* variants on TF promoter activity was assayed following PMA stimulation in comparison with mock-plasmid transfected cells (Mock). Luciferase activity was normalized to Renilla. Data represent means ± standard deviation. \**P*\<0.05. a.u, arbitrary units. n=3](1051677.fig3){#f3-1051677}

FHL2 physically interacts with tissue factor
--------------------------------------------

To investigate whether inhibition of TF by FHL2 is also attributable to this latter's physical interaction with TF, we performed co-immunoprecipitation experiments. Full-length TF co-immunoprecipitated efficiently with HA-tagged FHL2 from whole cell extracts using an anti-HA antibody ([Figure 4A](#f4-1051677){ref-type="fig"}), whereas ∆CT-TF, which lacks the intracellular cytoplasmic TF domain, failed to bind FHL2 ([Figure 4A](#f4-1051677){ref-type="fig"}), indicating that FHL2 requires the relatively short cytoplasmic tail of TF for its interaction. Pull-down assays using *FHL2* deletion mutants ([Figure 3C](#f3-1051677){ref-type="fig"}) revealed that all variants of FHL2 bind TF ([Figure 4B](#f4-1051677){ref-type="fig"}). It is known that FHL2 can enhance protein stability and to measure the effect of FHL2 on TF protein stability, we exposed cells to cycloheximide and determined the half-life of full-length TF and ΔCT-TF mutant proteins. The ΔCT-TF variant was more stable than full-length TF, but TF protein levels were not influenced by FHL2 ([Figure 4C, D](#f4-1051677){ref-type="fig"}). We concluded that FHL2 interacts with TF but does not affect TF protein stability.

![FHL2 physically interacts with tissue factor and inhibits tissue factor pro-coagulant activity. (A) HEK 293T cells were co-transfected with expression vectors encoding HA-tagged *FHL2* and full-length tissue factor (TF) or TF lacking the intracellular cytoplasmic TF domain (∆CT-TF), as indicated. Whole cell extracts were immunoprecipitated using the anti-HA antibody (IP: HA) and analyzed by western blotting (WB) with an anti-TF antibody (WB: TF and ∆CT-TF). Input of TF (Input TF and ∆CT-TF) and FHL2 (Input FHL2) were revealed on a separate blot. (B) HEK293T cells were co-transfected with expression vectors encoding HA-tagged *FHL2* variants and TF, as indicated. After immunoprecipitation with the anti-HA antibody (IP: HA) the samples were analyzed by western blotting with anti-TF antibody (WB: TF). Input samples were probed for *FHL2* variants (Input LIMs) and TF (Input TF). (C, D) HEK293T cells were transfected with expression plasmids coding for TF or ∆CT-TF with or without FHL2. Cells were treated with cycloheximide (CHX) to block *de novo* protein synthesis for 16 h. Tubulin was used as the loading control. Western blot analysis (C) and quantification of western blots (D); a.u, arbitrary units. (E, F) Human umbilical vein endothelial cells (HUVEC) and human micro-vascular endothelial cells (HMEC-1) were transduced with lentivirus encoding control shRNA (shCtrl) or shFHL2 followed by serum-starvation and treatment with tumor necrosis factor-α (TNFα). The generation of activated factor X (FXa) was measured. (G) FXa generation was assayed in smooth muscle cells (SMC) derived from WT and *FHL2*-KO mice following treatment with ionomycin. (H) FXa generation was assayed in human SMC upon ectopic expression of FHL2 or transduced with control lentivirus (Mock) and treatment with TNFα. n=3.](1051677.fig4){#f4-1051677}

FHL2 modulates tissue factor procoagulant activity
--------------------------------------------------

Having established that FHL2 interacts with TF and regulates TF expression in EC and SMC, we sought to examine the impact of FHL2 on the activity of TF in cultured EC and murine and human SMC, by assessing the potential of these cells to generate factor Xa (FXa). Knockdown of FHL2 in HUVEC and HMEC-1 resulted in enhanced TNFα-induced FXa generation compared to control ([Figure 4E, F](#f4-1051677){ref-type="fig"}). In a similar fashion, FHL2-deficient mouse SMC showed higher ionomycin-induced FXa generation than WT SMC ([Figure 4G](#f4-1051677){ref-type="fig"}). Ectopic expression of FHL2 resulted in a modest decrease of TNFα-induced FXa generation compared to that of control-transduced cells ([Figure 4H](#f4-1051677){ref-type="fig"}). Of note, following FHL2 knockdown in HMEC-1, we found, in the same cell lysates, that TF protein levels were increased 1.5-fold and that FXa generation was increased even more, 3-fold (*Online Supplementary Figure S5A, B*). These data indicate that FHL2 may regulate TF activity partly by binding the intracellular domain of TF and by modulating *TF* gene expression. [Figure 5](#f5-1051677){ref-type="fig"} is a schematic summary of our data.

![Schematic representation of FHL2 function in the modulation of tissue factor activity. The left panel shows the normal situation in which FHL2 inhibits tissue factor (TF) expression in activated endothelial cells (EC) and smooth muscle cells (SMC), whereas the right panel represents the effect of FHL2 deficiency, which results in enhanced TF expression and increased activity.](1051677.fig5){#f5-1051677}

Genetic variation in the *FHL2* gene is associated with venous thrombosis in humans
-----------------------------------------------------------------------------------

Having established that FHL2 reduces TF activity in EC and SMC, we reasoned that genetic variation in *FHL2* may affect venous thrombosis in man. We therefore analyzed 18 *FHL2* SNP and venous thrombosis risk in the INVENT consortium ([Table 1](#t1-1051677){ref-type="table"}). We observed that the *FHL2* polymorphism rs4851770 was associated with thrombosis risk with a *P*-value of 2x10^−4^, even after correction for multiple testing. No association was found between other tested SNP in the *FHL2* gene and risk of venous thrombosis ([Table 1](#t1-1051677){ref-type="table"}). Next, we sought for replication in the THE-VTE study. Individuals homozygous for the rs4851770C C-allele had a mildly increased risk of venous thrombosis compared with individuals homozygous for the T-allele (OR: 1.2; 95% CI: 0.7--1.4). The risk of idiopathic venous thrombosis was more pronounced (OR:1.53 (95% CI: 0.96 -- 2.45) ([Table 2](#t2-1051677){ref-type="table"}).

###### 

Validation of results of the single nucleotide polymorphism rs4851770 in the THE VTE cohort.

![](1051677.tab2)

Discussion
==========

Thrombosis-associated pathologies, such as VTE, myocardial infarction and stroke, are major causes of morbidity and mortality worldwide. TF is a key player in the extrinsic pathway of coagulation^[@b14-1051677]^ and although many experimental studies have helped us to understand the coagulation process, the regulation of TF expression and activity is incompletely understood. In the current study, we demonstrated that deficiency of FHL2 exacerbates thrombus formation in response to FeCl~3~-induced vascular injury. We revealed that FHL2 inhibits the expression of TF in activated vascular cells, including EC and SMC. Furthermore, we showed that FHL2 interacts with the intracellular domain of TF and inhibits TF activity. Additionally, we found that the *FHL2* rs4851770 polymorphism is associated with venous thrombosis in humans.

We previously demonstrated that *FHL2*-KO mice develop larger SMC-rich lesions in the murine carotid artery ligation model and here we observed that these lesions comprised, even 4 weeks after ligation, more thrombi than lesions in WT mice.^[@b30-1051677]^ The carotid artery ligation model is, however, not suitable for quantitative assessment of changes in venous thrombosis. For that reason, in this study we used the FeCl~3~-induced vascular injury model and established that *FHL2*-KO mice do indeed show exacerbated venous thrombus formation compared to WT mice.

SMC are the major source of TF in the FeCl~3~-induced model of vascular injury. Although there are some contrasting data on TF expression in EC, many studies demonstrated that TF is highly induced in endothelium under inflammatory conditions. Moreover, enhanced activity of TF is transient and directly correlates with increased mRNA levels.^[@b22-1051677]--[@b24-1051677]^ In the current study we found that overexpression of FHL2 inhibits TF expression, whereas FHL2 deficiency results in higher TF levels and activity. These observations were corroborated in HUVEC and microvascular HMEC-1 cells indicating that FHL2-mediated regulation of TF is not limited to larger vessels but may also occur in microvessels.

Thrombin is generated after TF exposure and is known to promote vascular neointima formation through multiple mechanisms, including activation of platelets and induction of SMC proliferation.^[@b41-1051677],[@b42-1051677]^ Given that FHL2 inhibits SMC proliferation^[@b28-1051677],[@b30-1051677]^ and our current observation that the level of active TF is increased in SMC deficient in FHL2, we hypothesize the following mechanism: in *FHL2*-KO mice enhanced TF expression promotes thrombin generation that in turn accelerates SMC proliferation causing enhanced lesion formation in the carotid artery ligation model. In addition to increased TF expression levels, we also observed that *FHL2*-KO SMC produce more pro-inflammatory cytokines than WT SMC, which may also contribute to the pro-thrombotic phenotype of *FHL2*-KO mice (*data not shown*). Further studies are warranted to investigate the hypothesis that thrombin actually mediates the increased SMC-rich lesion formation observed in *FHL2*-KO mice.

It is well established that the human *TF* gene contains binding sites for the transcription factors NFκB, AP-1, Sp-1 and Egr-1.^[@b25-1051677],[@b26-1051677]^ Interestingly, it has been reported that FHL2 is associated with these four transcription factors in multiple cell types in distinct contexts.^[@b29-1051677],[@b31-1051677],[@b43-1051677]^ Here, we demonstrated that FHL2 regulates TF-promoter activity through modulation of both NFκB and AP-1. The relative contribution of FHL2 in regulation of the activity of Egr-1 and Sp1 on the TF promoter is difficult to assess, because deletion of the respective response elements completely abrogates the activity of this promoter, as has been shown before. We found that FHL2 physically interacts with full-length TF, but not with the cytoplasmic tail-deleted mutant of TF (ΔCT-TF) indicating that FHL2 interacts intracellularly at the cell membrane with TF. This finding may relate to the interaction of FHL2 with several integrin units such as α~3~β~1~, which form a complex with TF.^[@b44-1051677],[@b45-1051677]^ It is not unlikely that FHL2 either stabilizes or abolishes the integrin α~3~ β~1~-TF complex, thereby affecting downstream signaling. Further studies are required to investigate the exact role of FHL2 in such TF complexes.

We explored the association between *FHL2* polymorphisms ([Table 1](#t1-1051677){ref-type="table"}) and venous thrombosis risk demonstrating that rs4851770 is associated. FHL2 was not previously known as a direct thrombo-modulator, although it has been shown to modulate the thrombosis-associated genes PAI-1^[@b46-1051677]^ and eNOS.^[@b47-1051677]^ At present, we can only speculate on the functional implication of the *FHL2* polymorphism rs4851770 in venous thrombosis. We postulate that this polymorphism affects the binding of specific transcription factors on the *FHL2* promoter, resulting in modulation of FHL2 expression and, as a consequence, regulates TF activity.

In summary, we demonstrated that FHL2 is a novel regulator of TF in vascular EC and SMC. Furthermore, we report that FHL2 regulates TF promoter activity partly through NFκB and AP-1. Finally, we showed that FHL2 physically interacts with full-length TF. This work reinforces the biological significance of FHL2 as a regulator of venous thrombosis, which may be of significance to identify individuals at risk of VTE, and suggest that enhancement of FHL2 expression may even be a target for intervention.
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